The Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market report provides current treatment practices, emerging drugs, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market share of the individual therapies, current and forecasted Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market Size from 2018 to 2030 segmented by seven major markets. The Report also covers current Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Overview
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is an uncommon inflammatory disease of small to medium-sized vessels that frequently presents with rapidly progressive glomerulonephritis and renal failure. However, it can affect any organ system.
Download free sample copy- https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market
List of regions covered in the report
List of companies involved in the report
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Types
granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA, formerly Churg-Strauss syndrome).
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Treatment Market
Treatment of AAV follows type- and activity-adapted regimens according to evidence from controlled trials which have been summarized in the EULAR (European League against Rheumatism) recommendations published in 2009.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Insights
For EGPA, the current approach to disease management is primarily based on reduction of active inflammation and suppression of the immune response through the use of corticosteroids and concomitant immunosuppressive therapy (e.g., methotrexate, azathioprine, and mycophenolate mofetil) and/or cytotoxic agents (e.g. cyclophosphamide). Although the use of these treatments can be effective for establishing remission, patients remain vulnerable to either the complications of the long-term use of these therapies and to the risk of relapse, particularly if the dose of corticosteroid is reduced.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Forecast
One large randomized noninferiority trial of patients with AAV has found Rituximab (RTX) to be noninferior to cyclophosphamide as induction therapy, including among the patients with renal involvement at enrollment. A randomized controlled trial comparing the effectiveness of daily oral cyclophosphamide versus intravenous pulses suggested that the pulse regimen significantly reduced cumulative exposure and was not associated with any significant difference in time to remission.
Other agents, including tacrolimus, intravenous immunoglobulin (IVIG) and anti-TNF-α compounds such as etanercept and infliximab, have previously been explored in the treatment of AAV, however, the current evidence supporting their use is limited and, in light of the demonstrable efficacy of other agents, are unlikely to be adopted as first-line induction therapy. Nevertheless, there are relatively few trials that have explored the efficacy of these agents in combination therapy.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Report Scope
Table of Content
1. Key Insights
2. Executive Summary of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
3. Competitive Intelligence Analysis for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
4. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Market Overview at a Glance
5. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Background and Overview
6. Patient Journey
7. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Treatment
11. Marketed Products
12. Emerging Therapies
13. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Report Highlights
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/